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Quebec City, Quebec, CanadaObjectives This study sought to determine the effects of chronic obstructive pulmonary disease
(COPD) on clinical outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) and
to determine the factors associated with worse outcomes in COPD patients.
Background Nodata exist on the factors determining poorer outcomes in COPD patients undergoing TAVI.
Methods A total of 319 consecutive patients (29.5% with COPD) who underwent TAVI were studied.
Functional status was evaluated by New York Heart Association (NYHA) functional class, Duke Activity
Status Index, and the 6-min walk test (6MWT) at baseline and at 6 to 12 months. The TAVI treatment
was considered futile if the patient either died or did not improve in NYHA functional class at 6-month
follow-up.
Results Survival rates at 1 year were 70.6% in COPD patients and 84.5% in patients without COPD
(p ¼ 0.008). COPD was an independent predictor of cumulative mortality after TAVI (hazard ratio: 1.84;
95% conﬁdence interval: 1.08 to 3.13; p ¼ 0.026). Improvement in functional status was observed after
TAVI (p < 0.001 for NYHA functional class, Duke Activity Status Index, and 6MWT), but COPD patients
exhibited less (p ¼ 0.036) improvement in NYHA functional class. Among COPD patients, a shorter
6MWT distance predicted cumulative mortality (p ¼ 0.013), whereas poorer baseline spirometry results
(FEV1 [forced expiratory volume in the ﬁrst second of expiration]) determined a higher rate of
periprocedural pulmonary complications (p ¼ 0.040). The TAVI treatment was futile in 40 COPD
patients (42.5%) and a baseline 6MWT distance <170 m best determined the lack of beneﬁt after TAVI
(p ¼ 0.002).
Conclusions COPD was associated with a higher rate of mortality at mid-term follow-up. Among COPD
patients, a higher degree of airway obstruction and a lower exercise capacity determined a higher risk of
pulmonary complications andmortality, respectively. TAVI was futile inmore than one-third of the COPD
patients, and a shorter distance walked at the 6MWT predicted the lack of beneﬁt after TAVI. These
results may help to improve the clinical decision-making process in this challenging group of patients.
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Abbreviations
and Acronyms
6MWT = 6-min walk test
BMI = body mass index
CI = conﬁdence interval
COPD = chronic obstructive
pulmonary disease
DASI = Duke Activity
Status Index
eGFR = estimated glomerular
ﬁltration rate
FEV1 = forced expiratory
volume in the ﬁrst second
of expiration
HR = hazard ratio
IQR = interquartile range
NYHA = New York Heart
Association
ROC = receiver-operating
characteristic
SAVR = surgical aortic
valve replacement
STS = Society of
Thoracic Surgeons
TA = transapical
TAo = transaortic
TAVI = transcatheter aortic
valve implantation
TF = transfemoral
VARC = Valve Academic
Research Consortium
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1073Chronic obstructive pulmonary disease (COPD) is a
pulmonary condition characterized by chronic airﬂow limi-
tation that is not fully reversible. In the management of
patients with severe aortic stenosis, COPD is present
in w19% of patients amenable to surgical aortic valve
replacement (SAVR) (1). In the past decade, transcatheter
aortic valve implantation (TAVI) has emerged as an alter-
native to SAVR in patients considered to be either inoper-
able or at very high surgical risk. COPD is one of the
main comorbidities leading to patients’ inoperability in
cardiac surgery, and it is therefore not surprising that as
many as 28% to 43% of the patients undergoing TAVI have
comorbid COPD (2–8).
In TAVI, COPD has been identiﬁed as a risk factor for
mortality (4,7,9), but no data exist to date on the prognostic
markers for periprocedural pulmonary complications or
mortality in this subgroup. A better knowledge of the factors
determining poorer outcomes in COPD patients would be
of major importance to improve both patient selection and
perioperative management. In pulmonary medicine, studies
of patients with COPD have identiﬁed a number of prog-
nostic markers for all-cause mortality (10,11), death from
respiratory causes, as well as hospitalization for acute exac-
erbations (12). These factors include increased age, body
mass index (BMI), severity of airway obstruction (forced
expiratory volume in the ﬁrst second of expiration [FEV1]),
and exercise capacity (6-min walk test [6MWT]); however,
the prognostic value of these 4 factors in COPD patients
undergoing TAVI has not been evaluated. Furthermore,
patients have signiﬁcant improvement in functional status
and quality of life (13,14) after TAVI, but little is known
about whether patients with COPD experience a similar
level of improvement. The objectives of our study were 2-
fold: 1) to determine the effects of COPD on clinical
outcomes and functional status; and 2) to evaluate the factors
that predict pulmonary complications, mortality, and treat-
ment futility in patients with COPD undergoing TAVI.
Methods
Study population and TAVI procedures. A total of 319
consecutive patients who underwent TAVI were studied.
Details of the evaluation process and the TAVI procedure
were described previously (4). In brief, a multidisciplinary
team that included 2 interventional cardiologists and
2 cardiac surgeons evaluated all potential TAVI candidates.
Depending on the degree of calciﬁcation, size of the iliofe-
moral arteries and severity of disease in the iliofemoral
arteries: transfemoral (TF) or transapical (TA)/transaortic
(TAo) approach were selected. All procedures were per-
formed with patients under general anesthesia and with
transesophageal echocardiography guidance. Data on
procedural success and major periprocedural complicationsas deﬁned by Valve Academic Research Consortium
(VARC) (15) were prospectively collected on pre-set data
collection forms. In-hospital pulmonary complications were
recorded and deﬁned as the occurrence of either nosocomial
pneumonia or respiratory failure necessitating re-intubation
and/or tracheotomy.
Functional status assessment: New York Heart Association func-
tional class, Duke Activity Status Index, and 6MWT. Functional
status evaluation was performed at baseline (within the month
before TAVI), at 6- to 12-month follow-up, and then yearly.
The Duke Activity Status Index
(DASI) questionnaire is a 12-item
scale ranging from 0 (worst) to
58.2 (best) that evaluates the
ability to perform common activi-
ties of daily living (Fig. 1) (16).
The 6MWT was performed in
accordance with the American
Thoracic Society protocol (17)
using a 30-m internal ﬂat corridor
marked by 2 orange trafﬁc cones.
Baseline 6MWT was not per-
formed in 23 patients because of
logistic reasons (6 patients with
COPD). Baseline 6MWT was
performed in 258 patients, and
38 patients unable to walk
(distance ¼ 0 m; 11 patients with
COPD) due to medical reasons
(New York Heart Association
[NYHA] functional class IV [n ¼
11], severely limited mobility [n ¼
21], and recent myocardial infarc-
tion [n¼ 6]) were also included in
the baseline 6MWT analysis. A
signiﬁcant improvement in func-
tional class (baseline vs. follow-up)
was deﬁned as a decrease of at
least 1 NYHA functional class or
an increase of >10% in DASI
score or 6MWT distance.
COPD assessment. COPD was
deﬁned according to Society of
Thoracic Surgeons (STS) deﬁnition, which is based on
spirometry results (FEV1 <75% predicted) and/or require-
ment for bronchodilator therapy. Information on broncho-
dilator therapies, long-term oral corticosteroid therapy, and
home oxygen therapy was recorded.
Follow-up. Clinical follow-up was conducted by clinical
visits and/or phone consultation. Patients were followed at 1,
6, and 12 months and annually thereafter, and no patient
was lost to follow-up. The occurrence of death during the
follow-up period was recorded and further classiﬁed as
Figure 1. The DASI Questionnaire
The DASI questionnaire is a 12-item scale ranging from 0 (worst) to 58.2 (best) that evaluates the ability to perform common activities of daily living. Reprinted with
permission from Hlatky et al. (16). DASI ¼ Duke Activity Status Index.
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1074cardiovascular (VARC criteria) or noncardiovascular. The
TAVI treatment was considered futile if death or a lack of
improvement in NYHA functional class occurred during the
6 months of follow-up.
Statistical analysis. Continuous variables are presented as
mean  SD or median (25th to 75th interquartile range
[IQR]) depending on variable distribution. Group com-
parisons were tested for differences with the Student
t test (paired Student t test for paired comparisons) or the
Wilcoxon test for continuous variables, and the chi-square
or Fisher exact test was used for categorical variables.
Comparisons of clinical outcomes between COPD and no-
COPD groups were adjusted for baseline differences between
groups using a logistic regression analysis that included vari-
ables with a p value<0.05 on univariate analysis. Baseline and
procedural variables exhibiting a p value <0.10 on univariate
analysis were included in a logistic regression analysis or a Cox
multivariate analysis to determine the predictive factors of
cumulative overall mortality. The variables included in the
multivariate analysis were sex, chronic atrial ﬁbrillation, esti-
mated glomerular ﬁltration rate (eGFR) <60 ml/min,
COPD, peripheral vascular disease, 6MWT, mean aortic
gradient, left ventricular ejection fraction, and TA/TAo
approach. In the COPD-TAVI cohort, baseline and proce-
dural variables exhibiting a p value <0.05 were included in
a logistic regression analysis or Cox multivariate analysis to
determine the predictive factors of periprocedural pulmonary
complications, cumulative overall mortality and futility. The
variables included in the analysis for the prediction of
pulmonary complications were: sex, FEV1, and oxygen
dependency. The variables included in the multivariate
analysis for the prediction of cumulative overall mortalitywere: eGFR<60 ml/min, DASI, and 6MWT. The variables
included in the prediction of treatment futility were:
eGFR <60 ml/min and 6MWT. Model performance was
evaluated using Hosmer-Lemeshow goodness-of-ﬁt test for
logistic regression models and Martingale residual plots for
Cox proportional hazards models. Receiver-operating char-
acteristic (ROC) curve analysis (greatest sumof sensitivity and
speciﬁcity) was used to discriminate threshold values of
6MWT and FEV1 to clinical outcomes. Survival curves up to
1 year were presented as Kaplan-Meier curves, and the log-
rank test was used for comparison between groups. A 2-way
analysis of variance or analysis of covariance for repeated
measures, followed by a Tukey post-hoc test was used to
evaluate the effects of time (baseline vs. discharge vs. follow-
up) and group (COPD vs. no COPD) on Doppler echocar-
diographic variables. The results were considered signiﬁcant
with p values <0.05. All analyses were conducted using the
SAS statistical package version 9.3 (SAS Institute Inc., Cary,
North Carolina).
Results
Of the 319 patients who underwent TAVI, 94 (29.5%) had
a diagnosis of COPD, with a mean FEV1 of 60  21% and
requiring a median of 2 (IQR: 1 to 3) inhaled bronchodilator
medications. Ten patients (10.6%) received long-term oral
glucocorticosteroid therapy and 8 patients (8.5%) were home
oxygen dependent. Baseline and procedural characteristics of
the study population, according to the presence of COPD,
are shown in Table 1.
30-day and late outcomes. Clinical outcomes after TAVI,
grouped according to the presence of COPD, are shown in
Table 1. Baseline and Procedural Characteristics of the Study Population According to the Presence of COPD
COPD
p Value
Study Population
(N ¼ 319)
No
(n ¼ 225)
Yes
(n ¼ 94)
Baseline variables
Age, yrs 80  8 80  8 78  8 0.053
Male 147 (46.1) 89 (39.6) 58 (61.7) <0.0001
BMI, kg/m2 26.8  5.4 26.4  5.2 27.8  5.7 0.039
NYHA functional class
I-II 63 (19.7) 53 (23.6) 10 (10.7) 0.008
III-IV 256 (80.3) 172 (76.4) 84 (89.4)
Smoker
Current 15 (4.7) 7 (3.1) 8 (8.5) 0.041
Previous 80 (25.1) 47 (20.9) 33 (35.1) 0.011
Diabetes 119 (37.3) 66 (29.3) 43 (45.7) 0.006
Hypertension 284 (89.0) 198 (88.0) 86 (91.5) 0.435
CAD 204 (63.9) 145 (64.4) 59 (62.8) 0.799
Previous MI 112 (35.1) 80 (35.6) 32 (34.0) 0.898
Previous AF 98 (30.7) 68 (30.2) 30 (31.6) 0.791
Previous CABG 123 (38.6) 85 (37.8) 38 (40.4) 0.706
Previous stroke 61 (19.1) 40 (17.8) 21 (22.3) 0.352
Peripheral vascular disease 111 (34.8) 63 (28.0) 48 (51.1) <0.0001
eGFR <60 ml/min 192 (60.2) 147 (65.3) 45 (47.9) 0.004
STS-PROM score 6.3 (4.1–8.9) 5.8 (3.8–8.3) 7.5 (5.5–10.3) <0.0001
Frailty 63 (19.8) 52 (23.1) 11 (11.7) 0.021
6MWT, m* 163 (62–253) 159 (63–250) 168 (60–267) 0.525
Echocardiographic variables
Mean aortic gradient, mm Hg 40  16 42  17 38  12 0.026
Aortic valve area index, cm2/m2 0.24 (0.20–0.30) 0.24 (0.20–0.29) 0.25 (0.21–0.30) 0.229
LVEF, % 54  14 54  14 53  15 0.919
SPAP, mm Hg 40 (33–50) 39 (32–47) 47 (35–55) 0.001
Procedural characteristics
Approach
TF 125 (39.2) 94 (41.8) 31 (32.9) 0.167
TA/Tao 194 (60.8) 131 (58.2) 63 (67.0)
Prosthesis type
Edwards SAPIENy 183 (57.4) 128 (56.9) 55 (58.5) 0.366
Edwards SAPIEN XTy 124 (38.9) 89 (39.6) 35 (37.2)
Edwards SAPIEN 3y 8 (2.5) 4 (1.8) 4 (4.3)
St. Jude Medical PORTICOz 4 (1.3) 4 (1.8) 0 (0.0)
Prosthesis size, mm
20 1 (0.3) 1 (0.4) 0 (0.0) 0.075
23 169 (52.9) 129 (57.3) 40 (42.6)
26 124 (38.9) 79 (35.1) 45 (48.0)
29 25 (7.9) 16 (7.1) 9 (9.7)
Procedural success 284 (89.0) 205 (91.1) 79 (84.0) 0.073
Values are mean  SD, n (%), or median (interquartile range). *Data from 296 patients; 88 patients in the COPD group. yEdwards Lifesciences,
Irvine, California. zSt. Jude Medical, St. Paul, Minnesota.
6MWT ¼ 6-min walk test; AF ¼ atrial ﬁbrillation; BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease;
COPD, chronic obstructive pulmonary disease; eGFR ¼ estimated glomerular ﬁltration rate; LVEF ¼ left ventricular ejection fraction; STS-PROM ¼
Society of Thoracic Surgeons predicted risk of mortality; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; NYHA ¼ New York
Heart Association; SPAP ¼ systolic pulmonary artery pressure; TA/TAo ¼ transapical/transaortic; TF ¼ transfemoral.
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1075Table 2. The 30-day mortality rates were similar between
groups (9.6% vs. 7.1%, p ¼ 0.578). There were no signiﬁ-
cant differences in VARC-deﬁned complications betweenCOPD and no-COPD patients; however COPD patients
had a higher rate of pulmonary complications (27.7% vs.
4.5%, p < 0.0001).
Table 2. 30-Day and Late Outcomes, According to the Presence of COPD
Study Population
(N ¼ 319)
COPD
OR/HR
(95% CI)* p Value
No
(n ¼ 225)
Yes
(n ¼ 94)
30-day outcomes
MI 4 (1.3) 2 (0.9) 2 (2.1) 2.42 (0.34–17.5) 0.380
Stroke 10 (3.1) 8 (3.6) 2 (2.1) 0.59 (0.12–2.83) 0.509
Major bleeding 34 (10.7) 20 (8.9) 14 (14.9) 1.82 (0.82–4.07) 0.141
Pulmonary complications 36 (11.4) 10 (4.5) 26 (27.7) 7.33 (3.11–17.3) <0.0001
Pneumonia 33 (10.4) 9 (4.0) 24 (25.5) 7.05 (2.87–17.3) <0.0001
Respiratory failure
requiring re-intubation or
tracheostomy
19 (5.9) 7 (3.1) 12 (12.8) 3.99 (1.39–11.45) 0.0100
Mortality 25 (7.8) 16 (7.1) 9 (9.6) 1.32 (0.51–3.30) 0.578
Length of stay, days 7 (5–10) 7 (5–9) 7 (5–14) d 0.133
Follow-up (>30 days) outcomes
MI 7 (2.2) 3 (1.4) 4 (4.4) 6.23 (1.20–32.4) 0.029
Stroke 4 (1.3) 3 (1.4) 1 (1.1) 0.89 (0.24–3.27) 0.854
Mortality (>30 days) 69 (21.6) 41 (18.2) 28 (29.8) 1.71 (0.98–3.00) 0.036
Cardiovascular mortality 32 (10.0) 21 (9.3) 11 (11.7) 1.35 (0.65–2.80) 0.428
Noncardiovascular death 37 (11.6) 20 (8.9) 17 (18.1) 2.18 (1.14–4.17) 0.019
Respiratory 14 (4.4) 2 (0.9) 12 (12.8) 13.52 (3.01–60.6) 0.0007
Malignancy 8 (2.5) 6 (2.9) 2 (2.1) 0.98 (0.20–4.85) 0.978
Renal failure 5 (1.7) 3 (1.4) 2 (2.1) 1.62 (0.27–9.77) 0.267
Multiorgan failure 2 (0.7) 1 (0.5) 1 (1.2) 2.75 (0.17–44.1) 0.199
Gastrointestinal tract defect 4 (1.4) 4 (1.9) 0 (0.0) d 0.328
Nonrespiratory sepsis 4 (1.4) 4 (1.9) 0 (0.0) d 0.328
Cumulative outcomes
MI 11 (3.5) 5 (2.2) 6 (6.4) 3.24 (0.77–13.7) 0.109
Stroke 14 (4.4) 11 (4.9) 3 (3.2) 0.80 (0.19–3.44) 0.768
Overall mortality 94 (29.5) 57 (25.3) 37 (39.4) 1.63 (1.02–2.60) 0.042
Cardiovascular mortality 46 (14.4) 29 (12.9) 17 (18.1) 1.34 (0.68–2.62) 0.396
Noncardiovascular death 48 (15.1) 28 (12.4) 20 (21.3) 1.95 (1.02–3.75) 0.044
Respiratory 19 (5.9) 6 (2.7) 13 (13.8) 6.17 (2.04–18.6) 0.001
Malignancy 8 (2.5) 6 (2.7) 2 (2.1) 1.38 (0.23–8.23) 0.726
Renal failure 5 (1.6) 3 (1.3) 2 (2.1) 4.01 (0.34–46.7) 0.268
Multiorgan failure 5 (1.6) 4 (1.8) 1 (1.1) 0.72 (0.07–7.19) 0.776
Gastrointestinal tract defect 6 (1.9) 5 (2.2) 1 (1.1) 0.65 (0.06–6.59) 0.713
Nonrespiratory sepsis 5 (1.6) 4 (1.8) 1 (1.1) 0.42 (0.04–4.52) 0.477
Values are n (%) or median (25th to 75th, interquartile range). *Values are expressed as OR for 30-day outcomes and HR for follow-up (>30-day)
outcomes and cumulative outcomes; p value refers to the signiﬁcance of the logistic regression analysis (OR) or Cox proportional hazard
regression (HR).
CI ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction; OR ¼ odds ratio.
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1076Median follow-up was 12 months (IQR: 7 to 25 months),
with no differences between groups (COPD: 12 months
[IQR: 7 to 25 months] vs. no COPD: 12 months [IQR: 7 to
25 months], p ¼ 0.614). A higher rate of late (>30-day)
mortality was observed in COPD patients (29.8% vs. 18.2%,
p ¼ 0.036), and this was related to a higher rate of
noncardiac death caused by respiratory failure in COPD
patients (12.8% vs. 0.9%, p < 0.001). Cumulative mortality
was signiﬁcantly higher in COPD patients compared with
no-COPD patients (39.4% vs. 25.3%, p ¼ 0.042). Kaplan-
Meier survival curves at 1-year follow-up are shown inFigure 2. The 1-year survival rate was signiﬁcantly lower in
COPD-TAVI patients compared with patients without
COPD (log-rank: 0.008) (Fig. 2). The rate of rehospitali-
zation for noncardiovascular causes at 1-year follow-up was
also much higher in COPD patients compared with the rest
of the study population (log-rank: 0.028) (Fig. 2).
The variables associated with a higher cumulative
mortality are shown in Table 3. COPD was associated with
a higher cumulative mortality rate on univariate analysis
(hazard ratio [HR]: 1.69; 95% conﬁdence interval [CI]: 1.11
to 2.55; p ¼ 0.014) and was identiﬁed as an independent
Figure 2. Kaplan-Meier Curves at 1-Year Follow-up According to the Presence of COPD
(A) Freedom from death. (B) Freedom from rehospitalization for cardiovascular causes. (C) Freedom from rehospitalization for noncardiovascular causes. (D) Freedom
from death or rehospitalization. COPD ¼ chronic obstructive pulmonary disease.
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1077predictor of cumulative late mortality in the multivariate
analysis (HR: 1.84; 95% CI: 1.08 to 3.13; p ¼ 0.026).
The echocardiographic results (valve hemodynamics,
pulmonary artery systolic pressure) of the study population
and according to the presence of COPD are shown in
Figure 3.
Functional status changes after TAVI. All TAVI patients
alive at 6 months had a NYHA functional class completed at
follow-up. DASI questionnaires were available in 228
patients at baseline and at follow-up (172 no-COPD
patients, 56 COPD patients). Of the 258 patients with
a 6MWT performed at baseline, 183 were alive and had
a minimum follow-up of 6 months, and of these, 156
patients (85%) had a 6MWT performed at 6 to 12 months
(120 no-COPD patients, 36 COPD patients). The changes
in functional status according to the presence of COPD are
shown in Table 4. As many as 80% of patients had improved
in NYHA functional class, but the rate of improvement was
lower (p ¼ 0.036) in COPD patients (71.6%) compared
with non-COPD patients (83.7%) (Table 4, Fig. 4).Functional status as evaluated by DASI improved in 72% of
the patients, with no differences between COPD and no-
COPD groups (Table 4). Most (72%) patients improved
their 6MWT distance, without differences between COPD
and no-COPD groups (Table 4).
Prognostic factors in COPD patients. Twenty-six of the 94
COPD patients (27.7%) had pulmonary complications
after TAVI. The variables associated with the occurrence
of periprocedural (30-day) pulmonary complications after
TAVI among COPD patients are shown in Table 5. Male
sex (p ¼ 0.027), a lower FEV1 (p ¼ 0.018), and oxygen
dependence (p¼ 0.026) were associated with a higher rate of
pulmonary complications on univariate analysis. The rate of
pulmonary complications tended to be lower in TF compared
with TA/TAo patients (16.1% vs. 33.3%, p ¼ 0.10). On
multivariate analysis, only a higher degree of airway
obstruction as determined by FEV1 was independently
associated with a higher rate of pulmonary complications
(odds ratio: 1.18 for each FEV1 decrease of 5%; 95% CI: 1.02
to 1.38; p ¼ 0.040) (Hosmer-Lemeshow goodness-of-ﬁt
Table 3. Univariate and Multivariate Predictors of Cumulative Overall Mortality (n ¼ 94 Events) in the
Study Population (N ¼ 319 Patients)
Univariate Analysis Multivariate Analysis
HR (95% CI) p Value HR (95% CI) p Value
Baseline variables
Age, yrs* 1.00 (0.97–1.02) 0.699
Male 1.75 (1.17–2.64) 0.016 1.98 (1.15–3.42) 0.013
BMI, kg/m2y 1.05 (1.00–1.10) 0.114
Smoker 1.11 (0.89–1.39) 0.351
Diabetes 1.20 (0.79–1.83) 0.403
Hypertension 1.29 (0.60–2.79) 0.520
CAD 1.35 (0.87–2.10) 0.177
Previous MI 1.39 (0.92–2.08) 0.116
Previous AF 1.84 (1.22–2.79) 0.004 1.36 (0.81–2.28) 0.246
Previous CABG 1.07 (0.71–1.61) 0.761
Previous stroke 0.26 (0.04–1.63) 0.150
Peripheral vascular disease 1.45 (0.96–2.17) 0.075 0.89 (0.52–1.51) 0.664
eGFR <60 ml/min 1.60 (1.02–2.48) 0.039 1.19 (0.69–2.05) 0.531
COPD 1.69 (1.11–2.55) 0.014 1.84 (1.08–3.13) 0.026
Frailty 1.04 (0.60–1.82) 0.882
6MWT, mz 1.10 (1.05–1.16) <0.001 1.11 (1.05–1.17) 0.004
Echocardiographic variables
Mean aortic gradient, mm Hg* 0.98 (0.97–0.99) 0.004 0.99 (0.99–1.01) 0.113
Aortic valve area index, cm2/m2y 1.94 (0.87–4.32) 0.110
LVEF, %* 0.99 (0.98–1.00) 0.094 1.00 (0.98–1.02) 0.990
SPAP, mm Hg* 1.01 (0.99–1.03) 0.125
Procedural characteristics
Approach TA/Tao 1.79 (1.09–2.94) 0.022 2.02 (1.04–3.95) 0.039
Procedural success 0.22 (0.03–1.59) 0.220
*For each increase by 1 U. yFor each decrease by 1 log-transformed unit. zFor each decrease in 6MWT by 20 m (data from 296 patients).
Abbreviations as in Tables 1 and 2.
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1078test: 6.31 with 8 df, p¼ 0.612). FEV1<60% of predicted was
identiﬁed as the cutoff point with the best sensitivity and
speciﬁcity for the prediction of pulmonary complications
after TAVI in COPD patients, with an area under the ROC
curve of 0.67 (95% CI: 0.54 to 0.79; p ¼ 0.026). Further-
more, COPD patients who experienced periprocedural
pulmonary complications had a higher 30-day mortality
(19.2% vs. 5.9%, p ¼ 0.047).
Thirty-seven COPD patients (39.4%) had died at follow-
up. The variables associated with a higher mortality after
TAVI among COPD patients are shown in Table 6. On
multivariate analysis, only a shorter distance walked in the
6MWT determined a higher risk of mortality (HR: 1.16
for each decrease in 20 m [95% CI: 1.06 to 1.27]),
p ¼ 0.013). A distance <150 m on the 6MWT was iden-
tiﬁed as the cutoff point for the prediction of cumulative
death after TAVI in COPD patients, with an area under the
ROC curve of 0.74 (95% CI: 0.63 to 0.84; p < 0.001). As
many as 75% of the patients who walked <150 m before
TAVI died at follow-up compared with 23.5% of the
patients who walked 150 m (p < 0.001).The TAVI treatment was considered futile (death or no
improvement in functional status at 6-month follow-up) in
40 COPD patients (42.5%). The clinical characteristics of
these patients compared with those who beneﬁtted from
the TAVI treatment are presented in Table 7. On multi-
variate analysis, a shorter distance walked in the baseline
6MWT determined a higher risk for treatment futility
(odds ratio: 1.16 [IQR: 1.02 to 1.19]; p ¼ 0.011)
(Hosmer-Lemeshow goodness-of-ﬁt test: 6.07 with 7 df,
p ¼ 0.532). A distance <170 m walked in the 6MWT was
identiﬁed as the best cutoff point for the prediction of
treatment futility, with an area under the ROC curve of
0.67 (95% CI: 0.55 to 0.78; p ¼ 0.002). The TAVI
treatment was futile in 59.1% of the patients who walked
<170 m before TAVI compared with 28.6% of the patients
who walked 170 m (p ¼ 0.005).
A total of 16 COPD patients were either oxygen
dependent (n ¼ 6), on long-term steroid therapy (n ¼ 8), or
both (n ¼ 2). The incidence of 30-day pulmonary compli-
cations and mortality in these patients was 50% and 6.3%,
respectively (62.5% and 12.5%, respectively, for those
Figure 3. Valve Hemodynamics and Pulmonary Artery Systolic Pressure
Changes After Transcatheter Aortic Valve Implantation According to the
Presence of COPD
(A) Changes in mean gradient and aortic valve area after transcatheter aortic
valve implantation. (B) Presence and degree of aortic regurgitation after
transcatheter aortic valve implantation. (C) Changes in pulmonary artery
pressure after TAVI. AR ¼ aortic regurgitation; AVA ¼ aortic valve area;
COPD ¼ chronic obstructive pulmonary disease; SPAP ¼ systolic pulmonary
artery pressure.
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1079oxygen dependent). After a median follow-up of 17 (IQR:
6 to 35) months, 8 of these 16 patients had died (50%;
62.5% of those oxygen dependent).
Discussion
COPD as a predictor of mortality. Several TAVI registries
and series have shown a relationship between COPD and
mortality (4,7,9) at up to 1-year follow-up. Moderate to
severe COPD remains an important reason for not per-
forming SAVR in elderly patients with severe aortic stenosis,
and it is thought that TAVI might be offered as a lower risk
alternative for the treatment of this group of patients. This
would explain the high rate (w30%) (2–9) of COPD
patients in TAVI studies. In accordance with the results of
previous TAVI studies, COPD appeared as one of the most
important predictors of mortality at mid-term follow-up in
our study, with a >1.5-fold higher risk of death among
COPD patients. Respiratory failure has been identiﬁed as
one of the main causes of late mortality after TAVI (4,6),
but no studies to date have focused on the causes of death in
COPD patients undergoing TAVI. The present study
showed that most COPD patients died either because of
pulmonary complications during the periprocedural period
or at mid-term because of respiratory failure secondary to
COPD. These results therefore highlight the importance of
determining the factors associated with poorer outcomes in
this high-risk group of patients.
Impact of COPD on functional status after TAVI. Previous
studies have shown that TAVI results in improvement in
quality of life and functional performance status (13,14).
However, it has been shown that one-ﬁfth to one-third of
patients fail to achieve a signiﬁcant improvement in func-
tional status and/or quality of life (13,14,18), and one may
wonder whether the presence of COPD may determine
a higher risk of this lack of improvement. The results of our
study showed a signiﬁcant improvement in functional status
as evaluated by NYHA functional class, DASI score, and
6MWT after TAVI. Although COPD patients exhibited
similar improvements in DASI score and 6MWT as the rest
of the study population, they had a higher NYHA functional
class at baseline and failed to achieve comparable improve-
ment in their NYHA functional class at follow-up. In
accordance with our ﬁndings, De Blois et al. (19) showed
that heart failure patients with COPD were overrated in
terms of NYHA functional class compared with patients
with a similar left ventricular ejection fraction, a reﬂection of
poorer exercise tolerance as a result of impaired lung func-
tion in COPD patients.
Predictors of poorer outcomes among COPD patients. In
respiratory medicine, studies of COPD patients have
developed a number of risk assessment tools for morbidity
and mortality. Celli et al. (10) introduced a risk score system
(BODE Index) incorporating risk factors associated with
Table 4. Functional Changes at 6- to 12-Month Follow-up According
to the Presence of COPD
COPD
p ValueNo Yes
DNYHA class*
Worsening/no change 33 (16.3) 21 (28.4) 0.036
Improvement 169 (83.7) 53 (71.6)
6MWT, my
Baseline 174 (110 to 255) 184 (118 to 286) 0.699
6 months 245 (179 to 333)z 256 (165 to 340)x 0.948
D6MWT, months 59 (4 to 119) 59 (16 to 99) 0.525
D6MWT
Worsening/no change 33 (27.5) 11 (30.6) 0.833
Improvement 87 (72.5) 25 (69.4)
DASIk
Baseline 9.9 (7.2 to 15.5) 10.8 (7.2 to 15.7) 0.675
6 mo 17.9 (9.9 to 26.9)z 15.5 (9.7 to 26.9)z 0.284
DDASI
Worsening/no change 40 (26.1) 17 (30.4) 0.609
Improvement 126 (73.3) 39 (69.6)
DDASI 6.3 (0 to 11.8) 3.9 (0.6 to 11.2) 0.293
Values are n (%) or median (25th to 75th, interquartile range). *Data available at baseline and at
follow-up for 276 patients (no COPD, 202; COPD, 74). yData available at baseline and at follow-
up for 156 patients (no COPD, 120; COPD, 36). zp < 0.0001 vs. baseline. xp ¼ 0.01 vs. baseline.
kData available at baseline and at follow-up for 228 patients (no COPD, 172; COPD, 56).
DASI ¼ Duke Activity Status Index; other abbreviations as in Table 1.
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1080increased mortality in COPD patients. The 4 factors of
the BODE Index, BMI (B), degree of airﬂow obstruction
(FEV1) (O), dyspnea (D), and exercise capacity as evaluated
by 6MWT (E) show an increased ability to predict mortality
compared with FEV1 alone. Puhan et al. (11) updated theFigure 4. Changes in NYHA Functional Class Over Time
NYHA functional class changes after transcatheter aortic valve implantation
according to the presence of COPD. Patients who died within the 6 months
after transcatheter aortic valve implantation (n ¼ 43) were not included in this
analysis. COPD ¼ chronic pulmonary obstructive disease; NYHA ¼ New York
Heart Association.BODE Index to include age as a prognostic factor for 3-year
mortality in the primary care management of COPD and
also demonstrated that the 6MWT was a much stronger
predictor of mortality than BMI or FEV1. Although the
BODE Index cannot be directly extrapolated to the TAVI
population, FEV1, and 6MWT, 2 of the factors included in
the BODE Index, were found to be predictors of clinical
outcomes in COPD patients undergoing TAVI in this
study.
The 6MWT has been used in a variety of clinical studies
to predict mortality. The SOLVD (Studies of Left Ven-
tricular Dysfunction) Trial investigators (20) showed
a higher mortality with a walked distance <300 m, whereas
a distance of <200 m predicted surgical mortality in patients
with COPD undergoing bilateral lung volume reduction
surgery (21). In the TOPAS (True or Pseudo Severe Aortic
Stenosis) study, a distance <320 m was a powerful predictor
of reduced survival in patients with low-ﬂow, low-gradient
aortic stenosis (22). Recently it was shown that in SAVR,
mortality at 12 months was associated with shorter preop-
erative 6MWT distances (23), and a cutoff distance of 300
m contributed to the risk stratiﬁcation of patients under-
going SAVR. Our study demonstrated an inverse correlation
of 6MWT distance with mortality and with treatment
futility in COPD-TAVI patients. A baseline distance<150 m
and <170 m best determined a higher risk of mortality and
treatment futility, respectively. The signiﬁcantly shorter cutoff
distance in our patients highlights the fact that TAVI patients
are more functionally impaired than patients with other life-
threatening conditions. Importantly, the majority (two-thirds)
of COPD patients who were not able to walk at least 170 m
before the TAVI procedure either died or did not improve
their NYHA functional class at follow-up. These ﬁndings
suggest that in COPD patients, the 6MWT may represent 1
baseline test that will ultimately contribute to a TAVI risk
index.
Pulmonary complications after surgical interventions are
a major attributable factor of morbidity, mortality, prolonged
hospital length of stay, and health care costs (24,25). Estab-
lished risk factors for post-operative pulmonary complications
have been well described and can be divided into patient- and
procedure-related factors (26). Procedure-related factors
include the use of general anesthesia, vascular surgery,
thoracic surgery, emergency surgery, and prolonged proce-
dures. All the TAVI procedures in our study were performed
with patients under general anesthesia; hence, we are unable
to draw any conclusions regarding general anesthesia as
a contributory risk factor. TF-TAVI can, however, be per-
formed with patients under local/regional anesthesia (27),
and the potential advantages of this approach versus general
anesthesia in patients with COPD merit further evaluation.
With regard to patient-related factors for pulmonary
complications, COPD has been shown to be an important
predictor of post-operative pulmonary complications (28).
Table 5. Predictors of Periprocedural (30-day) Pulmonary Complications (n ¼ 26) After TAVI in
COPD Patients (n ¼ 94)
Univariate Analysis Multivariate Analysis
OR (95% CI) p Value OR (95% CI) p Value
Baseline variables
Age, yrs* 1.05 (0.99–1.12) 0.123
Male 3.40 (1.15–10.10) 0.027 2.12 (0.56–8.04) 0.268
BMI, kg/m2y 1.07 (0.98–1.17) 0.129
NYHA functional class d 0.963
Smoker 0.97 (0.60–1.58) 0.908
Diabetes 1.95 (0.78–4.87) 0.154
Hypertension 1.16 (0.22–6.16) 0.861
CAD 0.74 (0.30–1.87) 0.530
Previous MI 0.63 (0.23–1.72) 0.370
Previous AF 0.55 (0.20–1.56) 0.259
Previous CABG 1.39 (0.56–3.45) 0.485
Previous stroke d 0.983
Peripheral vascular disease 1.45 (0.58–3.60) 0.428
eGFR <60 ml/min 0.91 (0.37–2.25) 0.837
Frailty 1.59 (0.42–5.94) 0.495
Porcelain aorta or severely calciﬁed aorta 0.22 (0.05–1.24) 0.112
DASI, %y 0.95 (0.88–1.03) 0.182
6MWT, mz 1.02 (0.94–1.11) 0.596
FEV1x 1.19 (1.03–1.38) 0.018 1.18 (1.02–1.38) 0.040
Pulmonary treatment
Bronchodilators, >2 1.79 (0.71–4.51) 0.216
Home oxygen 5.65 (1.23–25.95) 0.026 6.01 (0.95–37.87) 0.056
Glucocorticosteroids 1.93 (0.49–7.59) 0.346
Echocardiographic variables
Mean aortic gradient, mm Hg* 1.03 (0.99–1.06) 0.203
Aortic valve area index, cm2/m2y 1.51 (0.24–9.67) 0.663
LVEF, %* 1.02 (0.99–1.05) 0.286
SPAP, mm Hg* 1.02 (0.98–1.06) 0.295
Procedural characteristics
Approach TA/Tao 2.54 (0.84–7.63) 0.100
Procedural success 0.53 (0.14–2.04) 0.355
*For each increase by 1 unit. yFor each decrease by 1 log-transformed unit. zFor each decrease in 6MWT by 20 m (data from 88 patients). xFor
each decrease of FEV1 by 5%.
FEV1 ¼ forced expiratory volume in the ﬁrst second of expiration; TAVI ¼ transcatheter aortic valve implantation; other abbreviations as in
Tables 1 and 2.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 0 , 2 0 1 3 Mok et al.
O C T O B E R 2 0 1 3 : 1 0 7 2 – 8 4 COPD and TAVI
1081In more than one-fourth of our study’s COPD-TAVI
patients periprocedural pulmonary complications developed
compared with <5% of non-COPD patients. Furthermore,
approximately one-half of our study population were TA/
TAo-TAVI, resulting in our overall 11.4% overall pulmonary
complication rate (27.7% in COPD patients) comparable to
that found in a recent study on thoracotomy in octogenarians
(23.5%) (29). Although we could not identify TA/TAo-
TAVI as a contributing factor, TF-TAVI, which does not
alter thoracic wall mechanics, tended to be associated with
a lower rate of pulmonary complications in COPD-TAVI
patients. Importantly, a moderate degree of airway obstruc-
tion correlated with pulmonary complications in COPD-TAVI patients. The inverse correlation between FEV1 and
pulmonary complications emphasizes the potential role for
optimization of pulmonary function, as with cardiac and
general surgical procedures (29), before TAVI. In accordance
with previous surgical studies (24,25), the occurrence of
pulmonary complications was associated with a higher
mortality rate at 30 days.
Study limitations. COPD in this study was deﬁned accord-
ing to STS criteria and not the GOLD (Global initiative for
chronic Obstructive Lung Disease) deﬁnition. Although
less used in respiratory medicine, the STS deﬁnition has
been widely used in cardiac surgery, TAVI, and coronary
intervention studies (1–4,30). A signiﬁcant number of
Table 6. Univariate and Multivariate Predictors of Cumulative Overall Mortality (n ¼ 37) in Patients
With COPD (n ¼ 94)
Univariate Analysis Multivariate Analysis
HR (95% CI) p Value HR (95% CI) p Value
Baseline variables
Age, yrs* 1.05 (0.99–1.09) 0.050
Male 1.67 (0.84–3.31) 0.143
BMI, kg/m2y 1.01 (0.94–1.08) 0.670
NYHA functional class d 0.989
Smoker 0.98 (0.71–1.42) 0.981
Diabetes 0.93 (0.49–1.78) 0.826
Hypertension 0.70 (0.21–2.32) 0.561
CAD 1.05 (0.54–2.06) 0.884
Previous MI 1.15 (0.59–2.22) 0.672
Previous AF 1.14 (0.56–2.31) 0.728
Previous CABG 0.57 (0.28–1.15) 0.114
Previous stroke 1.24 (0.17–9.15) 0.832
Peripheral vascular disease 1.07 (0.54–2.13) 0.838
eGFR <60 ml/min 2.04 (1.05–3.98) 0.036 1.87 (0.91–3.84) 0.089
Frailty 0.57 (0.14–2.37) 0.436
Porcelain aorta or severely calciﬁed aorta 0.17 (0.04–1.73) 0.096
6MWT, mz 1.17 (1.07–1.28) 0.009 1.16 (1.06–1.27) 0.013
FEV1z 1.02 (0.92–1.15) 0.636
Pulmonary treatment
Bronchodilators, >2 1.30 (0.57–3.01) 0.533
Home oxygen 1.06 (0.41–2.79) 0.899
Glucocorticosteroids 1.43 (0.53–3.72) 0.458
Echocardiographic variables
Mean aortic gradient, mm Hg* 0.97 (0.94–0.99) 0.028 0.98 (0.95–1.01) 0.109
Aortic valve area index, cm2/m2y 1.72 (0.32–9.10) 0.526
LVEF, %* 1.00 (0.98–1.02) 0.983
SPAP, mm Hg* 1.01 (0.99–1.04) 0.334
Procedural characteristics
Approach TA/TAo 1.13 (0.51–2.51) 0.769
Procedural success 1.37 (0.60–3.12) 0.461
*For each increase by 1 unit. yFor each decrease by 1 log-transformed unit. zFor each decrease in 6MWT by 20 m (data from 88 patients).
Abbreviations as in Tables 1, 2, and 5.
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1082potential candidates for TAVI were unable to perform the
6MWT either at baseline or follow-up, mostly because of
poor mobility or logistic reasons, and this might have
introduced some bias in the ﬁnal results. However, baseline
6MWT was performed in most patients (82%), and close to
90% of surviving patients who had baseline 6MWT
repeated the test at follow-up, which allowed us an accurate
estimation of change in exercise capacity. The relatively low
number of fatal events at 30 days precluded performance of
a multivariate analysis to determine the prognostic role of
COPD on 30-day mortality. All TAVI procedures were
performed under general anesthesia and transesophageal
echocardiography guidance, and more than half of thepatients underwent the procedure by TA/TAo approach.
These results might therefore not apply to TAVI procedures
performed with local anesthesia and without thoracotomy,
and future studies will have to evaluate the impact of COPD
on patients undergoing this type of TAVI procedures.
Finally, the COPD cohort included a relatively small
number of patients, and the results regarding the prognostic
factors in COPD patients will have to be conﬁrmed in larger
studies. Also, larger studies will be needed to evaluate the
predictive factors of periprocedural complications (multi-
variate model slightly overﬁtted) and the prognostic value
of oxygen dependency or steroid therapy among COPD
patients.
Table 7. Main Baseline and Procedural Variables in COPD Patients According to the Occurrence of Treatment
Futility (Death or No Improvement in NYHA Functional Class at 6-Month Follow-up)
Treatment Futility
OR
(95% CI) p Value
No
(n ¼ 54)
Yes
(n ¼ 40)
Baseline variables
Age, yrs* 78  8 79  8 1.01 (0.96–1.06) 0.743
Male 32 (59.3) 26 (65.0) 1.22 (0.52–2.86) 0.649
BMI, kg/m2y 28  6 27  5 0.98 (0.91–1.06) 0.647
Smoker 6 (11.1) 2 (5.0) 0.84 (0.54–1.31) 0.436
Diabetes 26 (48.2) 17 (42.5) 0.80 (0.35–1.81) 0.587
Hypertension 50 (92.6) 36 (90.0) 0.72 (0.17–3.07) 0.657
CAD 35 (64.8) 24 (60.0) 0.81 (0.35–1.89) 0.633
Previous MI 17 (31.5) 15 (37.5) 1.31 (0.55–3.09) 0.543
Previous AF 18 (33.3) 12 (30.0) 0.86 (0.36–2.07) 0.732
Previous CABG 24 (44.4) 14 (35.0) 0.67 (0.29–1.56) 0.357
Previous stroke 0 2 (5.0) 999 (0.01–999) 0.979
Peripheral vascular disease 28 (51.9) 20 (50.0) 0.93 (0.41–2.10) 0.859
eGFR <60 ml/min 21 (38.9) 24 (60.0) 2.35 (1.02–5.44) 0.045
STS-PROM score* 8.0  4.6 9.2  5.0 1.05 (0.97–1.15) 0.240
Frailty 6 (11.1) 5 (12.5) 1.14 (0.32–4.05) 0.836
Porcelain aorta or severely calciﬁed aorta 14 (25.9) 7 (17.5) 0.61 (0.22–1.68) 0.335
DASI, %y 10.8 (7.2–17.9) 8.6 (7.2–14.9) 1.07 (0.99–1.14) 0.067
6MWT, mz 188 (118–316) 100 (33–206) 1.16 (1.02–1.19) 0.011
FEV1x 60.6  20.3 59.0  22.6 1.00 (0.97–1.02) 0.749
Pulmonary treatment
Bronchodilators, >2 36 (66.7) 27 (67.5) 1.50 (0.53–4.22) 0.443
Home oxygen 3 (5.6) 5 (12.5) 2.58 (0.58–11.58) 0.216
Glucocorticosteroids 4 (7.4) 6 (15.0) 2.42 (0.64–9.50) 0.190
Echocardiographic variables
Mean aortic gradient, mm Hg* 39.8  12.3 34.9  12.1 0.97 (0.93–1.00) 0.068
Aortic valve area index, cm2/m2y 0.27  0.06 0.26  0.07 1.88 (0.35–10.1) 0.463
LVEF, %* 53.7  14.2 53.1  15.1 0.99 (0.97–1.03) 0.838
SPAP, mm Hg* 46.8  12.8 47.0  14.6 1.00 (0.97–1.04) 0.952
Procedural characteristics
Approach TA/TAo 33 (61.1) 25 (62.5) 1.38 (0.56–3.39) 0.486
Procedural success 42 (77.8) 28 (70.0) 1.31 (0.43–4.03) 0.635
Values are mean  SD, median (interquartile range), or n (%). *For each increase by 1 unit. yFor each decrease by 1 log-transformed unit. zFor
each decrease in 6MWT by 20 m (data from 88 patients). xFor each decrease of FEV1 by 5%.
Abbreviations as in Tables 1, 2, and 4.
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1083Conclusions
In patients with severe symptomatic aortic stenosis under-
going TAVI, comorbid COPD is a major risk factor for
mortality at 1-year follow-up, driven by higher rates of death
from respiratory causes. A lower exercise capacity before the
intervention is an important predictor of mortality and
treatment futility among COPD patients, whereas a higher
degree of airway obstruction predicts periprocedural
pulmonary complications. These results highlight the
importance of a global pre-procedural functional and respi-
ratory assessment in COPD-TAVI patients as it may help
predict prognosis and patient selection. Future studies willhave to determine the potential usefulness of measures to
optimize pulmonary function pre- and post-TAVI to
improve clinical outcomes in patients with COPD.
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